×
About 3,973 results

ALLMedicine™ Narcolepsy Center

Research & Reviews  1,183 results

Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model...
https://doi.org/10.1093/brain/awab455
Brain : a Journal of Neurology; Bernard-Valnet R, Frieser D et. al.

May 14th, 2022 - Narcolepsy with cataplexy or narcolepsy type 1 is a disabling chronic sleep disorder resulting from the destruction of orexinergic neurons in the hypothalamus. The tight association of narcolepsy with HLA-DQB1*06:02 strongly suggest an autoimmune ...

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their signi...
https://doi.org/10.1093/sleep/zsac052
Sleep van der Hoeven AE, Fronczek R et. al.

May 14th, 2022 - The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hy...

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
https://clinicaltrials.gov/ct2/show/NCT05371483

May 13th, 2022 - This is an observational study evaluating how hypersomnia medications influence blood pressure and cognitive function in patients diagnosed with narcolepsy or idiopathic hypersomnia. Blood pressure will be assessed using 24-hour ambulatory blood p...

Gamma-Hydroxybutyrate Toxicity
https://emedicine.medscape.com/article/820531-print

May 12th, 2022 - Practice Essentials Gamma-hydroxybutyric acid (GHB) is a naturally occurring, 4-carbon compound with a structure similar to the neurotransmitter gamma-aminobutyric acid (GABA). GHB is described as a neurotransmitter and a regulator of energy metab...

A Study to Collect Information of People With Narcolepsy in Spain
https://clinicaltrials.gov/ct2/show/NCT04667338

May 10th, 2022 - This is a non-interventional, cross-sectional study with retrospective medical chart review conducted in public and private Spanish sleep clinics, to describe the management of adult participants diagnosed with narcolepsy defined by ICDS-3 in real...

see more →

Guidelines  1 results

Practice parameters for the treatment of narcolepsy and other hypersomnias of central o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276123
Sleep Morgenthaler TI, Kapur VK et. al.

Feb 6th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...

see more →

Drugs  213 results see all →

Clinicaltrials.gov  51 results

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
https://clinicaltrials.gov/ct2/show/NCT05371483

May 13th, 2022 - This is an observational study evaluating how hypersomnia medications influence blood pressure and cognitive function in patients diagnosed with narcolepsy or idiopathic hypersomnia. Blood pressure will be assessed using 24-hour ambulatory blood p...

A Study to Collect Information of People With Narcolepsy in Spain
https://clinicaltrials.gov/ct2/show/NCT04667338

May 10th, 2022 - This is a non-interventional, cross-sectional study with retrospective medical chart review conducted in public and private Spanish sleep clinics, to describe the management of adult participants diagnosed with narcolepsy defined by ICDS-3 in real...

An Open Label Study of FT218 in Subjects With Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04451668

May 5th, 2022 - This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (reg...

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04794491

Apr 27th, 2022 - The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.

Group Psychotherapy in Narcolepsy Type 1
https://clinicaltrials.gov/ct2/show/NCT05314556

Apr 6th, 2022 - The aim of this pilot study is to test the benefit of behavior therapy-oriented, method-integrated psychotherapy in an outpatient group setting in patients with narcolepsy type 1. Therefore we collect and evaluate initial data on its effectiveness...

see more →

News  128 results

Stimulant Reduces Apathy in Alzheimer's Disease
https://www.medpagetoday.com/neurology/alzheimersdisease/94722

Sep 27th, 2021 - Treatment with methylphenidate (Ritalin), a stimulant approved for attention deficit-hyperactivity disorders (ADHD) and narcolepsy, led to a small to medium reduction in apathy in people with Alzheimer's disease, the phase III ADMET 2 trial showed...

COVID-19 mRNA Vaccines: No Serious Health Risks in Large Study
https://www.medscape.com/viewarticle/958205

Sep 3rd, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Serious health risks were no more common in the first 3 weeks after Pfizer/BioNTech or Moderna COVID-19 vaccination compared with 22-42 days later...

Neurodegenerative nature of schizophrenia makes case for LAIs
https://www.mdedge.com/psychiatry/article/244762/schizophrenia-other-psychotic-disorders/neurodegenerative-nature
Jim Kling

Aug 27th, 2021 - Schizophrenia is a complex disease caused by dysfunction in specific brain regions or circuits. In fact, schizophrenia is not a single disease but several hundred different diseases, according to Henry A.

Neurodegenerative Nature of Schizophrenia Makes Case for LAIs
https://www.medscape.com/viewarticle/957383

Aug 27th, 2021 - Schizophrenia is a complex disease caused by dysfunction in specific brain regions or circuits. In fact, schizophrenia is not a single disease but several hundred different diseases, according to Henry A. Nasrallah, MD, who spoke on the topic at a...

FDA Approves First Drug for Idiopathic Hypersomnia
https://www.medscape.com/viewarticle/956533

Aug 12th, 2021 - UPDATED with comments August 13, 2032 // The US Food and Drug Administration (FDA) has approved an oral solution of calcium, magnesium, potassium, and sodium oxybates (Xywav) for the treatment of idiopathic hypersomnia in adults, the company annou...

see more →

Patient Education  13 results see all →